Michael C. Haffner

This paper develops a deep learning framework to infer gene expression from cell-free DNA, improving reliability and enabling functional genomics in precision oncology.

This paper introduces a 3D microdissection method combining CNC milling and light-sheet microscopy to study tumor evolution in complex 3D structures.

This study shows that IL-18-armored STEAP1 CAR T cells effectively treat Ewing sarcoma with reduced dose and improved efficacy.

This study evaluates Aclarubicin's safety and efficacy in pediatric cancer models, finding it effective with reduced genotoxicity and cardiotoxicity compared to doxorubicin.

This study identifies OGDHL as a regulator of tumor growth, neuroendocrine marker expression, and nucleotide abundance in prostate cancer, with implications for treatment resistance.

The paper identifies ITGA3B1 as a therapeutic target for metastatic bladder cancer using a phenotypic screening strategy and develops an ADC targeting this integrin complex, showing antitumor efficacy in preclinical models.

This study shows that acute CDK12 loss in prostate cancer causes HR deficiency via polyadenylation, but chronic loss leads to adaptation, making PARP inhibitors ineffective and suggesting CDK13 targeting as a new therapeutic approach.

The paper uses single-cell analysis to study how cell surface antigen expression changes in treatment-resistant prostate cancer, revealing transcriptional heterogeneity and shared gene regulatory networks between NEPC and SCLC.

The paper investigates how genomic alterations affect molecular networks in prostate cancer by integrating genomic, transcriptomic, and proteomic data from 105 samples, identifying a sub-network predictive of tumor aggressiveness and recurrence.